Abbott narrows 2026 adjusted diluted EPS guidance to $5.50-$5.55
ABT•Abbott narrowed its 2026 adjusted diluted EPS guidance to $5.50-$5.55, keeping the midpoint unchanged, and expects full-year comparable sales growth of about 6%. Third-quarter worldwide sales rose 7% on a comparable basis to $13 billion, while adjusted diluted EPS increased 9.2% to $1.42.
1. Guidance and quarterly results
Abbott narrowed its full-year 2026 adjusted diluted EPS guidance to $5.50-$5.55, reaffirming the midpoint, and expects comparable sales growth of approximately 6%. Third-quarter worldwide sales were $13 billion, up 7% on a comparable basis, and adjusted diluted EPS rose 9.2% to $1.42.
